Cite
HARVARD Citation
Sun, S. et al. (n.d.). 154P Neoadjuvant chemotherapy plus tislelizumab followed by adjuvant tislelizumab for locoregionally advanced nasopharyngeal carcinoma (NPC): A single-arm, phase II trial. Immuno-oncology technology. p. . [Online].